$CPIX
CUMBERLAND PHARMACEUTICALS INC

2024 Q4 Form 10-Q Financial Statement

#000162828024046730 Filed on November 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $9.086M
YoY Change -9.92%
Cost Of Revenue $1.323M
YoY Change -25.07%
Gross Profit $7.763M
YoY Change -6.7%
Gross Profit Margin 85.44%
Selling, General & Admin $7.073M
YoY Change -0.2%
% of Gross Profit 91.11%
Research & Development $1.306M
YoY Change -32.14%
% of Gross Profit 16.83%
Depreciation & Amortization $1.116M
YoY Change -10.44%
% of Gross Profit 14.38%
Operating Expenses $8.379M
YoY Change -7.02%
Operating Profit -$1.694M
YoY Change -9.22%
Interest Expense $137.4K
YoY Change 24.79%
% of Operating Profit
Other Income/Expense, Net $237.1K
YoY Change -71.15%
Pretax Income -$1.526M
YoY Change 44.42%
Income Tax $11.44K
% Of Pretax Income
Net Earnings -$1.544M
YoY Change 47.15%
Net Earnings / Revenue -16.99%
Basic Earnings Per Share -$0.11
Diluted Earnings Per Share -$0.11
COMMON SHARES
Basic Shares Outstanding 14.04M shares 14.10M shares
Diluted Shares Outstanding 14.05M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.46M
YoY Change -5.64%
Cash & Equivalents $17.46M
Short-Term Investments
Other Short-Term Assets $1.951M
YoY Change -1.0%
Inventory $4.510M
Prepaid Expenses
Receivables $11.31M
Other Receivables $0.00
Total Short-Term Assets $35.24M
YoY Change -15.64%
LONG-TERM ASSETS
Property, Plant & Equipment $312.0K
YoY Change -17.33%
Goodwill $914.0K
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.830M
YoY Change 10.72%
Total Long-Term Assets $41.51M
YoY Change -9.72%
TOTAL ASSETS
Total Short-Term Assets $35.24M
Total Long-Term Assets $41.51M
Total Assets $76.75M
YoY Change -12.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.06M
YoY Change 11.46%
Accrued Expenses $391.7K
YoY Change 17.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $5.989M
YoY Change
Total Short-Term Liabilities $31.09M
YoY Change 13.76%
LONG-TERM LIABILITIES
Long-Term Debt $10.10M
YoY Change -21.82%
Other Long-Term Liabilities $6.091M
YoY Change -5.64%
Total Long-Term Liabilities $6.091M
YoY Change -5.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.09M
Total Long-Term Liabilities $6.091M
Total Liabilities $52.28M
YoY Change 0.35%
SHAREHOLDERS EQUITY
Retained Earnings -$22.06M
YoY Change 97.11%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $24.78M
YoY Change
Total Liabilities & Shareholders Equity $76.75M
YoY Change -12.54%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$1.544M
YoY Change 47.15%
Depreciation, Depletion And Amortization $1.116M
YoY Change -10.44%
Cash From Operating Activities $475.5K
YoY Change -61.55%
INVESTING ACTIVITIES
Capital Expenditures $47.92K
YoY Change -49.6%
Acquisitions
YoY Change
Other Investing Activities $237.6K
YoY Change
Cash From Investing Activities $189.6K
YoY Change -299.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -536.8K
YoY Change -39.17%
NET CHANGE
Cash From Operating Activities 475.5K
Cash From Investing Activities 189.6K
Cash From Financing Activities -536.8K
Net Change In Cash 128.3K
YoY Change -50.44%
FREE CASH FLOW
Cash From Operating Activities $475.5K
Capital Expenditures $47.92K
Free Cash Flow $427.6K
YoY Change -62.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
TN
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
62-1765329
dei Entity Address Address Line1
EntityAddressAddressLine1
1600 West End Avenue
dei Entity Address State Or Province
EntityAddressStateOrProvince
TN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
37203
dei City Area Code
CityAreaCode
615
dei Local Phone Number
LocalPhoneNumber
255-0068
dei Security12b Title
Security12bTitle
Common stock, no par value
dei Trading Symbol
TradingSymbol
CPIX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18321624 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
11310625 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9758176 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
4509669 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
4609362 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
35236406 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
35714410 usd
CY2024Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
11831927 usd
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
12804529 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
312031 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
367903 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
19415232 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
22607918 usd
CY2024Q3 us-gaap Goodwill
Goodwill
914000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
914000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6208411 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6674394 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2829506 usd
CY2024Q3 us-gaap Assets
Assets
76747513 usd
CY2023Q4 us-gaap Assets
Assets
81776075 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
12057712 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14037629 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
391688 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
348092 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9085826 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10085926 usd
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1323013 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1765590 usd
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4397480 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4743142 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1306095 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1924768 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2675380 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2343855 usd
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1078290 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1175174 usd
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
10780258 usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001087294
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
Cumberland Pharmaceuticals Inc.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1300
dei Entity Address City Or Town
EntityAddressCityOrTown
Nashville
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14042304 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17464754 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2692921 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
11952529 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1694432 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1866603 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
69190 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
98603 usd
CY2024Q3 us-gaap Other Income
OtherIncome
0 usd
CY2023Q3 us-gaap Other Income
OtherIncome
0 usd
CY2024Q3 cpix Gain Loss Related To Settlement
GainLossRelatedToSettlement
0 usd
CY2023Q3 us-gaap Insured Event Gain Loss
InsuredEventGainLoss
346800 usd
CY2024Q3 us-gaap Interest Expense
InterestExpense
137374 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
110081 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1525527 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1056281 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11442 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6938 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-1536969 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-1063219 usd
CY2024Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
7112 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-13921 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1544081 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1049298 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14052754 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14277229 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14052754 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14277229 shares
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10085926 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27432376 usd
us-gaap Sublease Income
SubleaseIncome
400000 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
us-gaap Other Income
OtherIncome
2828871 usd
CY2024Q3 us-gaap Insured Event Gain Loss
InsuredEventGainLoss
237089 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1951358 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3025248 usd
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
CY2024Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
5988920 usd
CY2023Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12649195 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
13596528 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
31087515 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27982249 usd
CY2024Q3 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
10102672 usd
CY2023Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
12784144 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4997212 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5296247 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6090722 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6453566 usd
CY2024Q3 us-gaap Liabilities
Liabilities
52278121 usd
CY2023Q4 us-gaap Liabilities
Liabilities
52516206 usd
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2024Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14010736 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14010736 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14121833 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14121833 shares
CY2024Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
46843203 usd
CY2023Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
47091602 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-22064117 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17488161 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
24779086 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
29603441 usd
CY2024Q3 us-gaap Minority Interest
MinorityInterest
-309694 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
-343572 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
24469392 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
29259869 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
76747513 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
81776075 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27432376 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30199441 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4609499 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4536628 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12800469 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
13692535 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3523535 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4569476 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7800435 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7212731 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3288808 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3563493 usd
us-gaap Costs And Expenses
CostsAndExpenses
32022746 usd
us-gaap Costs And Expenses
CostsAndExpenses
33574863 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4590370 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3375422 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
227777 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
205854 usd
us-gaap Other Income
OtherIncome
0 usd
CY2023Q3 cpix Gain Loss Related To Settlement
GainLossRelatedToSettlement
475000 usd
cpix Gain Loss Related To Settlement
GainLossRelatedToSettlement
0 usd
cpix Gain Loss Related To Settlement
GainLossRelatedToSettlement
475000 usd
us-gaap Insured Event Gain Loss
InsuredEventGainLoss
237089 usd
us-gaap Insured Event Gain Loss
InsuredEventGainLoss
346800 usd
us-gaap Interest Expense
InterestExpense
382247 usd
us-gaap Interest Expense
InterestExpense
489069 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4507751 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7966 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
34327 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20813 usd
us-gaap Profit Loss
ProfitLoss
-4542078 usd
us-gaap Profit Loss
ProfitLoss
-28779 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
33878 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-43865 usd
us-gaap Net Income Loss
NetIncomeLoss
-4575956 usd
us-gaap Net Income Loss
NetIncomeLoss
15086 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14089496 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14343560 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14089496 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14521600 shares
us-gaap Profit Loss
ProfitLoss
-4542078 usd
us-gaap Profit Loss
ProfitLoss
-28779 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3406166 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3702687 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
855553 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
709021 usd
us-gaap Share Based Compensation
ShareBasedCompensation
227083 usd
us-gaap Share Based Compensation
ShareBasedCompensation
271146 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-936072 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1017712 usd
cpix Increase Decrease In Life Insurance Policies Over Premiums Paid
IncreaseDecreaseInLifeInsurancePoliciesOverPremiumsPaid
180081 usd
cpix Increase Decrease In Life Insurance Policies Over Premiums Paid
IncreaseDecreaseInLifeInsurancePoliciesOverPremiumsPaid
-16357 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
19377 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
11713 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-2691 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 usd
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
237089 usd
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
346800 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1552449 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-890361 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1072295 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-418355 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1022718 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1053432 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-645009 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2201773 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-667065 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1903021 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-362844 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-327329 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2516804 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5053700 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
64178 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
232595 usd
us-gaap Proceeds From Life Insurance Policies
ProceedsFromLifeInsurancePolicies
237556 usd
us-gaap Proceeds From Life Insurance Policies
ProceedsFromLifeInsurancePolicies
0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
88727 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
133739 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
84651 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-366334 usd
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
32988920 usd
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
23775000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
29681472 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
27051875 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
1251499 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
2108933 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
480666 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
551563 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1575283 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5937371 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-856870 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1250005 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18321624 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19757970 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17464754 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18507965 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
35974006 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
90156 usd
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
187961 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
172286 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
36048487 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
36048487 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
97877 usd
CY2023Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
171616 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
862154 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
36836902 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
36836902 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
83112 usd
CY2023Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
201237 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-1063219 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
35655558 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
29259869 usd
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
78754 usd
CY2024Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
246599 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-1902472 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
27189552 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
27189552 usd
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
71958 usd
CY2024Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
126689 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-1102637 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
26032184 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
26032184 usd
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
76371 usd
CY2024Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
102194 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-1536969 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
24469392 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates under different assumptions and conditions. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.</span></div>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1544081 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1049298 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14052754 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14277229 shares
CY2024Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14052754 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14277229 shares
us-gaap Net Income Loss
NetIncomeLoss
-4575956 usd
us-gaap Net Income Loss
NetIncomeLoss
15086 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14089496 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14343560 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
178040 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14089496 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14521600 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
600266 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
440389 shares
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9085826 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30199441 usd
CY2024Q3 us-gaap Sublease Income
SubleaseIncome
130000 usd
CY2023Q3 us-gaap Sublease Income
SubleaseIncome
160000 usd
us-gaap Sublease Income
SubleaseIncome
400000 usd
CY2024Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
20000.00 usd
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0 usd
CY2024Q3 us-gaap Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
12306377 usd
CY2023Q4 us-gaap Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
12619092 usd
CY2024Q3 us-gaap Other Inventory Materials Supplies And Merchandise Under Consignment
OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
154992 usd
CY2023Q4 us-gaap Other Inventory Materials Supplies And Merchandise Under Consignment
OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
149701 usd
CY2024Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3880227 usd
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4645098 usd
CY2024Q3 us-gaap Inventory Gross
InventoryGross
16341596 usd
CY2023Q4 us-gaap Inventory Gross
InventoryGross
17413891 usd
CY2024Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
11831927 usd
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
12804529 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
4509669 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
4609362 usd
CY2024Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
11831927 usd
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
12804529 usd
CY2021Q4 cpix Lessee Operating Lease Rent Increase
LesseeOperatingLeaseRentIncrease
0.025
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y9M18D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y7M6D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0938
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0940
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6208411 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6674394 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
391688 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
348092 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4997212 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5296247 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
5388900 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5644339 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
200000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
218311 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
836100 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
909911 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
934180 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
740791 usd
CY2024Q3 cpix Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
4847401 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8486694 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3097794 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
5388900 usd
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
342032 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
244305 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1041515 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
765455 usd
CY2024Q3 us-gaap Sublease Income
SubleaseIncome
129622 usd
CY2023Q3 us-gaap Sublease Income
SubleaseIncome
155025 usd
us-gaap Sublease Income
SubleaseIncome
408535 usd
us-gaap Sublease Income
SubleaseIncome
400524 usd
CY2024Q3 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
2500000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
22893 shares
CY2017Q4 cpix Stock Issued During Period Shelf Registration Proceeds From Sale Of Corporate Securities
StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities
100000000 usd
CY2024Q1 cpix Stock Issued During Period Shelf Registration Proceeds From Sale Of Corporate Securities
StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities
5800000 usd
CY2023Q3 us-gaap Line Of Credit Facility Expiration Period
LineOfCreditFacilityExpirationPeriod
P3Y
CY2024Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
44100000 usd
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001628280-24-046730-index-headers.html Edgar Link pending
0001628280-24-046730-index.html Edgar Link pending
0001628280-24-046730.txt Edgar Link pending
0001628280-24-046730-xbrl.zip Edgar Link pending
cpix-20240930_cal.xml Edgar Link unprocessable
cpix-20240930_def.xml Edgar Link unprocessable
a2024q3-exhibit311.htm Edgar Link pending
a2024q3-exhibit312.htm Edgar Link pending
a2024q3-exhibit321.htm Edgar Link pending
cpix-20240930.htm Edgar Link pending
cpix-20240930.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
cpix-20240930_lab.xml Edgar Link unprocessable
cpix-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cpix-20240930_htm.xml Edgar Link completed
report.css Edgar Link pending
Show.js Edgar Link pending